Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring. Athira, which went public in 2020 ...

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Athira had clung to the hope that its experimental drug fosgonimeton could overcome a phase 2 failure in Alzheimer’s to demonstrate success in Parkinson’s and dementia. Unfortunately, a mid ...

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going. Just a couple of weeks after announcing that ...

BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

Leen Kawas resigned as Athira's CEO in October 2021 after an investigation into her doctoral work. She's now forging a new path with a life sciences investment firm and telling her side of the story.

Athira Pharma’s experimental Alzheimer’s disease drug has failed a Phase 2 clinical trial and the working theory as to why is that the small molecule does not play well with widely prescribed ...

Athira Pharma’s stock has sold off some months ago on its Alzheimer’s drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show ...

Litton. Athira’s 2023 Pipeline Outlook: Status and Upcoming Milestones Fosgonimeton (ATH-1017) - Small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its ...

Stressing the importance of integrity in taxpayer-funded biomedical research, the U.S. Department of Justice reported that Athira Pharma Inc. agreed to pay more than $4 million to resolve False Claims ...